

Listing of Claims

1-8. (canceled)

9. (currently amended) A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist is selected from the group consisting of d) a WISP-1 immunoadhesin; e) a WISP-1 polypeptide linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene; f) a WISP-1 antibody; and d) a WISP-1 variant.

10. (canceled)

11. (currently amended) The method of claim 9, wherein said anti-WISP-1 antibody binds native human WISP-1 comprising amino acids 23-367 of FIGS. 9A-9C (SEQ ID NO:1) or one or more domains of WISP-1 polypeptide comprising amino acids encoded by the sequences of SEQ ID NO:3, 4, 5, 6, 7, 8, 9, 10 or 11.

12. (original) The method of claim 9 or 11, wherein said anti-WISP-1 antibody is a chimeric, humanized or human antibody.

13. (original) The method of claim 9, wherein said mammalian cells comprise cancer cells.

14. (original) The method of claim 13, wherein said mammalian cells comprise colon or colorectal cancer cells, breast cancer cells, lung cancer cells or brain cancer cells.

15-30. (canceled)